{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:18:22Z","timestamp":1791919102828,"version":"4.3.4"},"reference-count":103,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T00:00:00Z","timestamp":1682553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Korea Drug Development Fund funded by the Ministry of Science and ICT; Ministry of Trade, Industry, and Energy; and Ministry of Health and Welfare","award":["HN21C1058"],"award-info":[{"award-number":["HN21C1058"]}]},{"name":"Korea Drug Development Fund funded by the Ministry of Science and ICT; Ministry of Trade, Industry, and Energy; and Ministry of Health and Welfare","award":["2022M3A9G1014520"],"award-info":[{"award-number":["2022M3A9G1014520"]}]},{"name":"Korea Drug Development Fund funded by the Ministry of Science and ICT; Ministry of Trade, Industry, and Energy; and Ministry of Health and Welfare","award":["2023R1A2C2003034"],"award-info":[{"award-number":["2023R1A2C2003034"]}]},{"name":"Korea Drug Development Fund funded by the Ministry of Science and ICT; Ministry of Trade, Industry, and Energy; and Ministry of Health and Welfare","award":["2019M3D1A1078940"],"award-info":[{"award-number":["2019M3D1A1078940"]}]},{"name":"Korea Drug Development Fund funded by the Ministry of Science and ICT; Ministry of Trade, Industry, and Energy; and Ministry of Health and Welfare","award":["2019R1A6A1A11051471"],"award-info":[{"award-number":["2019R1A6A1A11051471"]}]},{"name":"National Research Foundation of Korea","award":["HN21C1058"],"award-info":[{"award-number":["HN21C1058"]}]},{"name":"National Research Foundation of Korea","award":["2022M3A9G1014520"],"award-info":[{"award-number":["2022M3A9G1014520"]}]},{"name":"National Research Foundation of Korea","award":["2023R1A2C2003034"],"award-info":[{"award-number":["2023R1A2C2003034"]}]},{"name":"National Research Foundation of Korea","award":["2019M3D1A1078940"],"award-info":[{"award-number":["2019M3D1A1078940"]}]},{"name":"National Research Foundation of Korea","award":["2019R1A6A1A11051471"],"award-info":[{"award-number":["2019R1A6A1A11051471"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Autoimmune neuroinflammatory diseases are a group of disorders resulting from abnormal immune responses in the nervous system, causing inflammation and tissue damage. The interleukin (IL) family of cytokines, especially IL-1, IL-6, and IL-17, plays a critical role in the pathogenesis of these diseases. IL-1 is involved in the activation of immune cells, production of pro-inflammatory cytokines, and promotion of blood-brain barrier breakdown. IL-6 is essential for the differentiation of T cells into Th17 cells and has been implicated in the initiation and progression of neuroinflammation. IL-17 is a potent pro-inflammatory cytokine produced by Th17 cells that plays a crucial role in recruiting immune cells to sites of inflammation. This review summarizes the current understanding of the roles of different interleukins in autoimmune neuroinflammatory diseases, including multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer\u2019s disease, neuromyelitis optica, and autoimmune encephalitis, and discusses the potential of targeting ILs as a therapeutic strategy against these diseases. We also highlight the need for further research to better understand the roles of ILs in autoimmune neuroinflammatory diseases and to identify new targets for treating these debilitating diseases.<\/jats:p>","DOI":"10.3390\/ijms24097960","type":"journal-article","created":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T02:27:56Z","timestamp":1682648876000},"page":"7960","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":96,"title":["Autoimmune Neuroinflammatory Diseases: Role of Interleukins"],"prefix":"10.3390","volume":"24","author":[{"given":"Abdul Waheed","family":"Khan","sequence":"first","affiliation":[{"name":"Department of Molecular Science and Technology, Ajou University, Suwon 16499, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3923-4712","authenticated-orcid":false,"given":"Mariya","family":"Farooq","sequence":"additional","affiliation":[{"name":"Department of Molecular Science and Technology, Ajou University, Suwon 16499, Republic of Korea"},{"name":"S&K Therapeutics, Ajou University Campus Plaza 418, 199 Worldcup-ro, Yeongtong-gu, Suwon 16502, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moon-Jung","family":"Hwang","sequence":"additional","affiliation":[{"name":"Department of Molecular Science and Technology, Ajou University, Suwon 16499, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1224-8276","authenticated-orcid":false,"given":"Muhammad","family":"Haseeb","sequence":"additional","affiliation":[{"name":"S&K Therapeutics, Ajou University Campus Plaza 418, 199 Worldcup-ro, Yeongtong-gu, Suwon 16502, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5920-7848","authenticated-orcid":false,"given":"Sangdun","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Molecular Science and Technology, Ajou University, Suwon 16499, Republic of Korea"},{"name":"S&K Therapeutics, Ajou University Campus Plaza 418, 199 Worldcup-ro, Yeongtong-gu, Suwon 16502, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Thompson, K.K., and Tsirka, S.E. (2017). The Diverse Roles of Microglia in the Neurodegenerative Aspects of Central Nervous System (CNS) Autoimmunity. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18030504"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"664664","DOI":"10.3389\/fneur.2021.664664","article-title":"Autoimmune Disorders of the Nervous System: Pathophysiology, Clinical Features, and Therapy","volume":"12","author":"Bhagavati","year":"2021","journal-title":"Front. Neurol."},{"key":"ref_3","first-page":"437231","article-title":"A Potential Link between Environmental Triggers and Autoimmunity","volume":"2014","author":"Vojdani","year":"2014","journal-title":"Autoimmune Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/CM9.0000000000001929","article-title":"Interleukins in the treatment of melanoma","volume":"135","author":"Xu","year":"2022","journal-title":"Chin. Med. J."},{"key":"ref_5","unstructured":"Vaillant, A.A.J., and Qurie, A. (2020). StatPearls, StatPearls Publishing."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.jaci.2010.11.050","article-title":"Interleukins, from 1 to 37, and interferon-\u03b3: Receptors, functions, and roles in diseases","volume":"127","author":"Akdis","year":"2011","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/35094583","article-title":"Cytokines and acute neurodegeneration","volume":"2","author":"Allan","year":"2001","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1523\/JNEUROSCI.2830-13.2014","article-title":"Trans-Signaling Is a Dominant Mechanism for the Pathogenic Actions of Interleukin-6 in the Brain","volume":"34","author":"Campbell","year":"2014","journal-title":"J. Neurosci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.4103\/1673-5374.355767","article-title":"Neutrophil-derived interleukin-17A participates in neuroinflammation induced by traumatic brain injury","volume":"18","author":"Liu","year":"2023","journal-title":"Neural Regen. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1358\/dnp.2006.19.2.977443","article-title":"Pathophysiology of interleukin-23 in experimental autoimmune encephalomyelitis","volume":"19","author":"Touil","year":"2006","journal-title":"Drug News Perspect."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"727956","DOI":"10.3389\/fphar.2021.727956","article-title":"The Role of IL-36 in the Pathophysiological Processes of Autoimmune Diseases","volume":"12","author":"Chen","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1007\/s12017-021-08656-0","article-title":"IL-2\/IL-2R antibody complex enhances Treg-induced neuroprotection by dampening TNF-\u03b1 inflammation in an In Vitro stroke model","volume":"23","author":"Borlongan","year":"2021","journal-title":"Neuromolecular Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"828447","DOI":"10.3389\/fimmu.2022.828447","article-title":"Interleukins and Ischemic Stroke","volume":"13","author":"Zhu","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Porro, C., Cianciulli, A., and Panaro, M.A. (2020). The Regulatory Role of IL-10 in Neurodegenerative Diseases. Biomolecules, 10.","DOI":"10.3390\/biom10071017"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.4103\/1673-5374.336134","article-title":"Exploring the role of interleukin-27 as a regulator of neuronal survival in central nervous system diseases","volume":"17","author":"Hackam","year":"2022","journal-title":"Neural Regen. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00535-020-01689-5","article-title":"Interleukin-35 promotes the differentiation of regulatory T cells and suppresses Th2 response in IgG4-related type 1 autoimmune pancreatitis","volume":"55","author":"Ito","year":"2020","journal-title":"J. Gastroenterol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.sjpain.2017.08.002","article-title":"Targeting cytokines for treatment of neuropathic pain","volume":"17","author":"Hung","year":"2017","journal-title":"Scand. J. Pain"},{"key":"ref_18","unstructured":"MS International Federation (2013). Atlas of MS 2013: Mapping multiple sclerosis around the world. Mult. Scler. Int. Fed., 2013, 1\u201328."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e1029","DOI":"10.1212\/WNL.0000000000007035","article-title":"The prevalence of MS in the United States: A population-based estimate using health claims data","volume":"92","author":"Wallin","year":"2019","journal-title":"Neurology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S1474-4422(10)70064-8","article-title":"The changing demographic pattern of multiple sclerosis epidemiology","volume":"9","year":"2010","journal-title":"Lancet Neurol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1136\/jnnp.2008.171132","article-title":"Multiple sclerosis: The bare essentials","volume":"9","author":"Coles","year":"2009","journal-title":"Pract. Neurol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000351153","article-title":"Global Epidemiology of Amyotrophic Lateral Sclerosis: A Systematic Review of the Published Literature","volume":"41","author":"Logroscino","year":"2013","journal-title":"Neuroepidemiology"},{"key":"ref_23","unstructured":"Revi, M. (2020). GeNeDis 2018: Genetics and Neurodegeneration, Springer."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Alzheimer\u2019s Association (2020). Alzheimer\u2019s disease facts and figures. Alzheimers Dement., 16, 391\u2013460.","DOI":"10.1002\/alz.12068"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/ana.25131","article-title":"Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis","volume":"83","author":"Dubey","year":"2018","journal-title":"Ann. Neurol."},{"key":"ref_27","first-page":"1","article-title":"Multiple Sclerosis: Pathogenesis, Symptoms, Diagnoses and Cell-Based Therapy","volume":"19","author":"Ghasemi","year":"2017","journal-title":"Cell J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/01720610-201208000-00005","article-title":"CME ARTICLE Multiple sclerosis: A comprehensive review for the physician assistant","volume":"25","author":"Browning","year":"2012","journal-title":"J. Am. Acad. Physician Assist."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"647588","DOI":"10.3389\/fimmu.2021.647588","article-title":"Circulating Interleukins and Risk of Multiple Sclerosis: A Mendelian Randomization Study","volume":"12","author":"Lu","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12974-022-02408-y","article-title":"Central nervous system macrophages in progressive multiple sclerosis: Relationship to neurodegeneration and therapeutics","volume":"19","author":"Kamma","year":"2022","journal-title":"J. Neuroinflamm."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/1756-185X.12290","article-title":"Interleukin-17 and interleukin-23: Importance in the pathogenesis of lung impairment in patients with systemic sclerosis","volume":"17","author":"Katulska","year":"2014","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0022-510X(96)00283-3","article-title":"IL-6 detection in multiple sclerosis brain","volume":"146","author":"Maimone","year":"1997","journal-title":"J. Neurol. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.32598\/rmm.8.1.1","article-title":"The Role of Interleukin-6 as an Indicator of Multiple Sclerosis Progression from Relapse Remitting to Secondary Progressive Status","volume":"8","author":"Eslami","year":"2020","journal-title":"Res. Mol. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S0165-5728(99)00139-3","article-title":"IL-6 plays a crucial role in the induction phase of myelin oligodendrocyte glycoprotein 35\u201355 induced experimental autoimmune encephalomyelitis","volume":"101","author":"Okuda","year":"1999","journal-title":"J. Neuroimmunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jneuroim.2018.03.017","article-title":"Anti-IL-6 receptor antibody improves pain symptoms in mice with experimental autoimmune encephalomyelitis","volume":"319","author":"Serizawa","year":"2018","journal-title":"J. Neuroimmunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jns.2017.08.395","article-title":"Potential benefits of the anti-IL-6 receptor antibody tocilizumab in multiple sclerosis patients with high plasmablast frequency","volume":"381","author":"Araki","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.imlet.2015.01.001","article-title":"The role of Th17 cells in patients with relapsing-remitting multiple sclerosis: Interleukin-17A and interleukin-17F serum levels","volume":"164","author":"Babaloo","year":"2015","journal-title":"Immunol. Lett."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"566","DOI":"10.4049\/jimmunol.177.1.566","article-title":"IL-17 Plays an Important Role in the Development of Experimental Autoimmune Encephalomyelitis","volume":"177","author":"Komiyama","year":"2006","journal-title":"J. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.2174\/1389450117666160307144027","article-title":"IL-17A and Multiple Sclerosis: Signaling Pathways, Producing Cells and Target Cells in the Central Nervous System","volume":"17","author":"Kolbinger","year":"2016","journal-title":"Curr. Drug Targets"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/nm1651","article-title":"Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation","volume":"13","author":"Kebir","year":"2007","journal-title":"Nat. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12974-015-0335-3","article-title":"Interleukin-22 is increased in multiple sclerosis patients and targets astrocytes","volume":"12","author":"Perriard","year":"2015","journal-title":"J. Neuroinflamm."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"577062","DOI":"10.1016\/j.jneuroim.2019.577062","article-title":"Impact of interferon \u03b2-1b, interferon \u03b2-1a and fingolimod therapies on serum interleukins-22, 32\u03b1 and 34 concentrations in patients with relapsing-remitting multiple sclerosis","volume":"337","author":"Shaker","year":"2019","journal-title":"J. Neuroimmunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jns.2014.05.009","article-title":"IL1-\u03b2 expression in multiple sclerosis","volume":"343","author":"Maghzi","year":"2014","journal-title":"J. Neurol. Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1212\/WNL.45.6_Suppl_6.S16","article-title":"Cytokine localization in multiple sclerosis lesions: Correlation with adhesion molecule expression and reactive nitrogen species","volume":"45","author":"Brosnan","year":"1995","journal-title":"Neurology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/brain\/awh707","article-title":"Myelin-laden macrophages are anti-inflammatory, consistent with foam cells in multiple sclerosis","volume":"129","author":"Boven","year":"2006","journal-title":"Brain"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Prins, M., Eriksson, C., Wierinckx, A., Bol, J.G.J.M., Binnekade, R., Tilders, F.J.H., and Van Dam, A.-M. (2013). Interleukin-1\u03b2 and Interleukin-1 Receptor Antagonist Appear in Grey Matter Additionally to White Matter Lesions during Experimental Multiple Sclerosis. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0083835"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1056\/NEJM200105313442207","article-title":"Amyotrophic lateral sclerosis","volume":"344","author":"Rowland","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1002\/ana.21543","article-title":"Current hypotheses for the underlying biology of amyotrophic lateral sclerosis","volume":"65","author":"Rothstein","year":"2009","journal-title":"Ann. Neurol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"9094","DOI":"10.1038\/s41598-017-09097-1","article-title":"Increased peripheral blood inflammatory cytokine levels in amyotrophic lateral sclerosis: A meta-analysis study","volume":"7","author":"Hu","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e959","DOI":"10.1038\/cddis.2013.491","article-title":"Dysregulated microRNAs in amyotrophic lateral sclerosis microglia modulate genes linked to neuroinflammation","volume":"4","author":"Parisi","year":"2013","journal-title":"Cell Death Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jneuroim.2009.02.012","article-title":"Immune system alterations in sporadic amyotrophic lateral sclerosis patients suggest an ongoing neuroinflammatory process","volume":"210","author":"Mantovani","year":"2009","journal-title":"J. Neuroimmunol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Garbuzova-Davis, S., Ehrhart, J., Sanberg, P.R., and Borlongan, C.V. (2018). Potential Role of Humoral IL-6 Cytokine in Mediating Pro-Inflammatory Endothelial Cell Response in Amyotrophic Lateral Sclerosis. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19020423"},{"key":"ref_53","first-page":"305","article-title":"Tocilizumab attenuates inflammation in ALS patients through inhibition of IL6 receptor signaling","volume":"1","author":"Mizwicki","year":"2012","journal-title":"Am. J. Neurodegener. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/1721727X0900700105","article-title":"Increased Il-8 Levels in the Cerebrospinal Fluid of Patients with Amyotrophic Lateral Sclerosis","volume":"7","author":"Mennini","year":"2009","journal-title":"Eur. J. Inflamm."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12974-015-0350-4","article-title":"Humoral factors in ALS patients during disease progression","volume":"12","author":"Ehrhart","year":"2015","journal-title":"J. Neuroinflamm."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1523\/JNEUROSCI.0854-15.2016","article-title":"IL-10 Controls Early Microglial Phenotypes and Disease Onset in ALS Caused by Misfolded Superoxide Dismutase 1","volume":"36","author":"Gravel","year":"2016","journal-title":"J. Neurosci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1600-0404.2010.01333.x","article-title":"Interleukin-17 and interleukin-23 are elevated in serum and cerebrospinal fluid of patients with ALS: A reflection of Th17 cells activation?","volume":"122","author":"Rentzos","year":"2010","journal-title":"Acta Neurol. Scand."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1742-2094-7-76","article-title":"IL-17A is increased in the serum and in spinal cord CD8 and mast cells of ALS patients","volume":"7","author":"Fiala","year":"2010","journal-title":"J. Neuroinflamm."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"26224","DOI":"10.1073\/pnas.1912954116","article-title":"Alzheimer\u2019s disease: A clinical perspective and future nonhuman primate research opportunities","volume":"116","author":"Haque","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1126\/science.1197623","article-title":"Decreased clearance of CNS \u03b2-amyloid in Alzheimer\u2019s disease","volume":"330","author":"Mawuenyega","year":"2010","journal-title":"Science"},{"key":"ref_61","first-page":"1121","article-title":"The role of cerebral amyloid \u03b2 accumulation in common forms of Alzheimer disease","volume":"115","author":"Gandy","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e975","DOI":"10.1038\/cddis.2013.503","article-title":"Oligomeric amyloid \u03b2 induces IL-1\u03b2 processing via production of ROS: Implication in Alzheimer\u2019s disease","volume":"4","author":"Parajuli","year":"2013","journal-title":"Cell Death Dis."},{"key":"ref_63","first-page":"1868","article-title":"Microglia in the Neuroinflammatory Pathogenesis of Alzheimer\u2019s Disease and Related Therapeutic Targets","volume":"13","author":"Cai","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1182\/blood.V87.6.2095.bloodjournal8762095","article-title":"Biologic basis for interleukin-1 in disease","volume":"87","author":"Dinarello","year":"1996","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/0197-4580(96)00104-2","article-title":"In vivo and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis","volume":"17","author":"Sheng","year":"1996","journal-title":"Neurobiol. Aging"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0197-4580(01)00287-1","article-title":"Interleukin-1, neuroinflammation, and Alzheimer\u2019s disease","volume":"22","author":"Mrak","year":"2001","journal-title":"Neurobiol. Aging"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"6539","DOI":"10.4049\/jimmunol.1100620","article-title":"Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal \u03b2-catenin pathway function in an Alzheimer\u2019s disease model","volume":"187","author":"Kitazawa","year":"2011","journal-title":"J. Immunol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1742-2094-9-21","article-title":"Sequence variants of interleukin 6 (IL-6) are significantly associated with a decreased risk of late-onset Alzheimer\u2019s disease","volume":"9","author":"Chen","year":"2012","journal-title":"J. Neuroinflamm."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.bbi.2019.08.005","article-title":"IL-6 trans-signaling in the brain influences the behavioral and physio-pathological phenotype of the Tg2576 and 3xTgAD mouse models of Alzheimer\u2019s disease","volume":"82","author":"Escrig","year":"2019","journal-title":"Brain Behav. Immun."},{"key":"ref_70","first-page":"55","article-title":"Study of interleukin-6 production in Alzheimer\u2019s disease","volume":"49","author":"Cojocaru","year":"2011","journal-title":"Romanian J. Intern. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s12035-014-8657-1","article-title":"Body Fluid Cytokine Levels in Mild Cognitive Impairment and Alzheimer\u2019s Disease: A Comparative Overview","volume":"50","author":"Brosseron","year":"2014","journal-title":"Mol. Neurobiol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/1742-2094-9-199","article-title":"Pro-inflammatory interleukin-18 increases Alzheimer\u2019s disease-associated amyloid-\u03b2 production in human neuron-like cells","volume":"9","author":"Sutinen","year":"2012","journal-title":"J. Neuroinflamm."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"E2705","DOI":"10.1073\/pnas.1604032113","article-title":"IL-33 ameliorates Alzheimer\u2019s disease-like pathology and cognitive decline","volume":"113","author":"Fu","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"107530","DOI":"10.1016\/j.celrep.2020.107530","article-title":"IL-33-PU.1 Transcriptome Reprogramming Drives Functional State Transition and Clearance Activity of Microglia in Alzheimer\u2019s Disease","volume":"31","author":"Lau","year":"2020","journal-title":"Cell Rep."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12974-021-02249-1","article-title":"Neuromyelitis optica spectrum disorders: From pathophysiology to therapeutic strategies","volume":"18","author":"Contentti","year":"2021","journal-title":"J. Neuroinflamm."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12883-021-02198-5","article-title":"The possible role of Interleukin-6 as a regulator of insulin sensitivity in patients with neuromyelitis optica spectrum disorder","volume":"21","author":"Maghbooli","year":"2021","journal-title":"BMC Neurol."},{"key":"ref_78","unstructured":"Weinshenker, B.G., and Wingerchuk, D. (2017). Mayo Clinic Proceedings, Elsevier."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"577925","DOI":"10.1016\/j.jneuroim.2022.577925","article-title":"IL-6 as a marker for NMOSD disease activity","volume":"370","author":"Haramati","year":"2022","journal-title":"J. Neuroimmunol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1073\/pnas.1017385108","article-title":"Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica","volume":"108","author":"Chihara","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e311","DOI":"10.1212\/NXI.0000000000000311","article-title":"Effects of neuromyelitis optica\u2013IgG at the blood\u2013brain barrier in vitro","volume":"4","author":"Takeshita","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"169","DOI":"10.7861\/clinmedicine.19-2-169","article-title":"Neuromyelitis optica spectrum disorders","volume":"19","author":"Huda","year":"2019","journal-title":"Clin. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1177\/1352458510379247","article-title":"Cytokine and chemokine profiles in neuromyelitis optica: Significance of interleukin-6","volume":"16","author":"Uzawa","year":"2010","journal-title":"Mult. Scler. J."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1007\/s00415-009-5274-4","article-title":"Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis","volume":"256","author":"Uzawa","year":"2009","journal-title":"J. Neurol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3109\/00207450903428970","article-title":"Enhanced IL-6 production in aquaporin-4 antibody positive neuromyelitis optica patients","volume":"120","year":"2010","journal-title":"Int. J. Neurosci."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Maciak, K., Pietrasik, S., Dziedzic, A., Redlicka, J., Saluk-Bijak, J., Bijak, M., W\u0142odarczyk, T., and Miller, E. (2021). Th17-Related Cytokines as Potential Discriminatory Markers between Neuromyelitis Optica (Devic\u2019s Disease) and Multiple Sclerosis\u2014A Review. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22168946"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.jocn.2011.01.031","article-title":"Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis during relapse","volume":"18","author":"Wang","year":"2011","journal-title":"J. Clin. Neurosci."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jneuroim.2019.01.015","article-title":"The expansion of circulating IL-6 and IL-17-secreting follicular helper T cells is associated with neurological disabilities in neuromyelitis optica spectrum disorders","volume":"330","author":"Monteiro","year":"2019","journal-title":"J. Neuroimmunol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"589288","DOI":"10.3389\/fneur.2020.589288","article-title":"Markedly Elevated Serum Level of T-Helper Cell 17-Related Cytokines\/Chemokines in Acute Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis","volume":"11","author":"Kang","year":"2020","journal-title":"Front. Neurol."},{"key":"ref_91","first-page":"267","article-title":"Serum levels of IL-6 and IL-17 in multiple sclerosis, neuromyelitis optica patients and healthy subjects","volume":"11","author":"Ashtari","year":"2019","journal-title":"Int. J. Physiol. Pathophysiol. Pharmacol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.imbio.2019.02.008","article-title":"Interleukin-36 alpha levels are elevated in the serum and cerebrospinal fluid of patients with neuromyelitis optica spectrum disorder and correlate with disease activity","volume":"224","author":"Song","year":"2019","journal-title":"Immunobiology"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12883-019-1415-2","article-title":"Increased serum IL-36\u03b2 and IL-36\u03b3 levels in patients with neuromyelitis optica spectrum disorders: Association with disease activity","volume":"19","author":"Yang","year":"2019","journal-title":"BMC Neurol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.3389\/fpsyt.2021.775017","article-title":"Autoimmune Encephalitis and Autism Spectrum Disorder","volume":"12","author":"Whiteley","year":"2021","journal-title":"Front. Psychiatry"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1007\/s00415-019-09590-9","article-title":"The autoantibody-mediated encephalitides: From clinical observations to molecular pathogenesis","volume":"268","author":"Ramanathan","year":"2021","journal-title":"J. Neurol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s13311-016-0471-1","article-title":"Interleukin-6 Blockade as Rescue Therapy in Autoimmune Encephalitis","volume":"13","author":"Dale","year":"2016","journal-title":"Neurotherapeutics"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"fcac196","DOI":"10.1093\/braincomms\/fcac196","article-title":"Cytokine dynamics and targeted immunotherapies in autoimmune encephalitis","volume":"4","author":"Birzu","year":"2022","journal-title":"Brain Commun."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"684","DOI":"10.3389\/fneur.2019.00684","article-title":"Neuronal NMDAR Currents of the Hippocampus and Learning Performance in Autoimmune Anti-NMDAR Encephalitis and Involvement of TNF-\u03b1 and IL-6","volume":"10","author":"Wang","year":"2019","journal-title":"Front. Neurol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1007\/s13311-016-0442-6","article-title":"Tocilizumab in Autoimmune Encephalitis Refractory to Rituximab: An Institutional Cohort Study","volume":"13","author":"Lee","year":"2016","journal-title":"Neurotherapeutics"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"673021","DOI":"10.3389\/fimmu.2021.673021","article-title":"Cerebrospinal Fluid IL-17A Could Predict Acute Disease Severity in Non-NMDA-Receptor Autoimmune Encephalitis","volume":"12","author":"Levraut","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1093\/abbs\/gmy137","article-title":"Th17 cells were recruited and accumulated in the cerebrospinal fluid and correlated with the poor prognosis of anti-NMDAR encephalitis","volume":"50","author":"Zeng","year":"2018","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/1742-2094-10-117","article-title":"Suppression of experimental autoimmune encephalomyelitis by interleukin-10 transduced neural stem\/progenitor cells","volume":"10","author":"Klose","year":"2013","journal-title":"J. Neuroinflamm."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Lavasani, S., Dzhambazov, B., Nouri, M., F\u00e5k, F., Buske, S., Molin, G., Thorlacius, H., Alenfall, J., Jeppsson, B., and Westr\u00f6m, B. (2010). A Novel Probiotic Mixture Exerts a Therapeutic Effect on Experimental Autoimmune Encephalomyelitis Mediated by IL-10 Producing Regulatory T Cells. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0009009"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/9\/7960\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:24:49Z","timestamp":1760124289000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/9\/7960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,27]]},"references-count":103,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["ijms24097960"],"URL":"https:\/\/doi.org\/10.3390\/ijms24097960","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,27]]}}}